Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...
While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...
Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...
The Cool Down on MSN2h
Drugmaker reveals unsettling details of new strategy amid public outrage: 'It will be worse before it gets better'A Danish drugmaker has revealed a stunning increase in pollution amid plans to boost production of its popular weight loss ...
(Reuters) -KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG, Bloomberg News reported on ...
Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...
24/7 Wall St. on MSN18h
3 Rock-Solid Dividend Stocks That Will Grow Passive Income This YearDividend stocks have been a reliable cornerstone for those who want to anchor their portfolios when markets get shaky. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback